OBJECTIVES: In this study, we analyzed the consumption trends of oral antidiabetics in Morocco in the private sector, during the 1997-2014 period and the impact of generics’ penetration and the Medical Insurance System launch since 2004. METHODS: We used sales data in volume from the ATC system : the consumption volumes were converted in defined daily doses (DDD). RESULTS: between 1997 and 2014, outpatients consumption of oral antidiabetics (OAD) in Morocco went from 1,9 to 14 DDD/1000 inhabitants/day habitants/jour (7,8 time more). The consumption increased significantly since 2005 due to the launch of Public Medical Insurance System (called “AMO”), inducing a significant increase in OAD consumption growth : from (+8,8%) during the 1997-2004 period to (+13,7%) during the 2005-2014 period. This evolution is mainly due to the : -          Increase of sulfonylureas consumption (multiplied by 4) during this period, with the launch of « Amaryl^® » in 1999 and its generics since 2006 and medical guidelines supporting sulfa drugs use. -          Increase of Metformin (biguanides’ class) consumption (multiplied by 10), supported by medical guidelines recommending Metformin as preferred initial therapy. -          The consumption of innovating therapies marketed in Morocco since 2008 in monotherapy or biotherapy (DPPIV inhibitors) increased dramatically : as an example, Janumet® reached 11% of total OADs’ consumption in 6 years. CONCLUSIONS: The consumption of oral antidiabetics increased significantly in Morocco during the 1997-2014 period due medical guidelines in favor of some OADs (sulfonylureas, biguanides..), generics’ penetration, and the launch of innovative therapies, like DPPIV inhibitors, in Morocco.